Marker Therapeutics, Inc. (NASDAQ:MRKR) Financings
Financings
| Raise | Date |
|---|---|
| At-the-market programme of common stock Tranche closed: US$10M raised Use of proceeds: Extending the company's cash runway well into 2026 | Nov 14, 2025 |
| Private placement of common stock (or pre-funded warrants) and accompanying warrants Announced: US$16.1M · US$3.2 a share · Warrants at US$4.03 for 60 months · Canaccord Genuity +1 Dealers: Canaccord Genuity (lead), Brookline Capital Markets, a division of Arcadia Securities, LLC Buyers: Blue Owl Healthcare Opportunities; New Enterprise Associates (NEA); Aisling Capital Use of proceeds: Support clinical advancement of the Phase 1 APOLLO study of MT-601 in lymphoma, among other uses | Dec 19, 2024 |